Daratumumab for multidrug-resistant phospholipase-A2 receptor–related membranous nephropathy

At least 10% of patients with anti–phospholipase-A2 receptor antibody (aPLA2R)–associated membranous nephropathy do not attain immunologic remission with standard therapies. Anti–plasma cell therapy with bortezomib has been suggested.1,2 We report the disease course in a patient treated with daratumumab, a human monoclonal anti-CD38 antibody approved for treatment of multiple myeloma and amyloid light-chain amyloidosis.